Synta files $115M IPO

Perhaps buoyed by a string of positive data, 2004 Fierce 15 winner Synta Pharmaceuticals is filing a $115 million IPO despite the risky biotech IPO climate. The Lexington, MA biotech has yet to determine the number of shares to be offered and the price range for the offering. Earlier this month the FDA granted Synta fast-track status for its lead oncology drug candidate, STA-4783. Synta is developing small molecule drugs for a number of indications, including cancer and chronic inflammatory diseases.

- see the company press release

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.